ACTRN12616000043437已完成1 期
A phase 1, randomised, placebo-controlled, double-blind, cross-over study to evaluate systemic bioavailability of oral OTS167 under fed and fasting conditions in healthy adult subjects.
CMAX - a division of IDT Australia0 个研究点目标入组 11 人开始时间: 2016年1月19日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 11
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Treatment
- 盲法
- Blinded (masking used)
入排标准
- 年龄范围
- 45 Years 至 o limit（—）
- 性别
- All
入选标准
- •Healthy males or females aged 45 years or over
- •- Females must be of non-child bearing potential
排除标准
- •- Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic or allergic diseases.
- •- Orthostatic blood pressure changes
研究者
相似试验
招募中
不适用
A phase 1, randomized, placebo-controlled, double-blind, single center, multiple-dose, parallel trial evaluating the impact of apraglutide on gastric emptying of liquids in healthy subjectsShort Bowel SyndromeNL-OMON53626VectivBio AG36
未知
1 期
A phase 1, randomized, placebo-controlled, double-blind, multiple oral dose study of DS-8500a in Japanese healthy male subjectsJPRN-jRCT2080223495DAIICHI SANKYO CO., LTD.36
已完成
1 期
A single and multiple dose study of M127101 in healthy subjectsasal polyp accompanies eosinophilic chronic rhinosinusitisJPRN-jRCT2071230019Tomoyuki Nishiura16
已完成
不适用
A Phase 1, Randomized, Placebo-Controlled, Double-Blind, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL919 in Healthy ParticipantsAlzheimers10012303Alzheimer's DiseaseNL-OMON51440Denali Therapeutics Inc.80
已完成
1 期
Study of ZYN002 (cannabidiol gel) in 40 Healthy VolunteersMental Health - Other mental health disordersNeurological - EpilepsyMusculoskeletal - OsteoarthritisHuman Genetics and Inherited Disorders - Other human genetics and inherited disordersEpilepsyFragile X SyndromeOsteoarthritisACTRN12618000183280Zynerba Pharmaceuticals Pty. Ltd.40